mRNA Cancer Vaccine Begins Trials for Non-Small Cell Lung Cancer
An mRNA vaccine has entered human trials as a treatment for lung cancer. Unlike traditional cancer vaccines such as the HPV vaccine, BNT116 is a therapeutic cancer vaccine designed to reduce tumor growth in patients with cancer or prevent its recurrence.
Pfizer’s RSV Vaccine ABRYSVO Approved by FDA
The U.S. Food and Drug Administration (FDA) has approved ABRYSVO (respiratory syncytial virus vaccine [RSV]), a bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
Changes in Immune Cell Gene Activity May Indicate Probability of Developing MS
A new study sheds like on the role of cytotoxic T cells in developing multiple sclerosis.
FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease
The U.S. Food and Drug Administration has expanded its approval of Dupixent to chronic obstructive pulmonary disease (COPD).
FDA Approves New Treatment for Hemophelia A and B
The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies).
New Gene Therapies Are Transformative for People with Sickle Cell Disease and Frequent Vaso-Occlusive Crises
Affecting more than 100,000 American children and adults, sickle cell disease is an inherited hemoglobinopathy that results when a single-nucleotide mutation in the ß-globin gene yields an abnormal “sickle” hemoglobin (HbS). Now, these patients may be eligible for a one-time gene therapy that offers the potential of a durable functional cure by eliminating severe VOCs and associated hospitalizations.
FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease
The U.S. Food and Drug Administration (FDA) has expanded its approval of Dupixent to chronic obstructive pulmonary disease (COPD).
Xembify Receives Expanded Label for PI Patients
The U.S. Food and Drug Administration (FDA) has approved an expanded label for Grifols’ XEMBIFY (20% subcutaneous immune globulin [SCIG]) to include treatment-naïve patients with primary humoral immunodeficiencies (PI).
COVID Vaccines: What’s Available Now and What’s in the Works?
Three top vaccine producers are making newer vaccines that not only protect against the newer sublineages of COVID-19, but that also protect against other respiratory viruses.
Viruses, Variants and Vaccines: Staying Ahead of the Spread
Although history has proven the success of vaccines in controlling the spread of diseases, emerging threats are concerning. However, hope is on the horizon with studies of newer vaccines.
